Nov 13, 2024
Pulmatrix and Cullgen Announce Proposed Merger
Nov 08, 2024
Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Aug 13, 2024
Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update
May 15, 2024
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)
May 10, 2024
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update
Mar 28, 2024
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
Jan 08, 2024
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives
May 27, 2020
Pulmatrix to Host 2020 Annual Meeting of Stockholders Virtually
Jan 30, 2020
Pulmatrix Receives Fast Track Designation for Pulmazole for the Treatment of Asthma-ABPA
Jan 16, 2020
Pulmatrix Regains Compliance with Nasdaq Minimum Bid Price Requirement
Jan 02, 2020
Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson
May 16, 2019
Pulmatrix Announces Leadership Change
Apr 08, 2019
Pulmatrix, Inc. Announces Closing of $16.6 Million Upsized Public Offering
Apr 03, 2019
Pulmatrix, Inc. Announces Pricing of $14.4 Million Upsized Public Offering
Feb 08, 2019
Pulmatrix, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market
Feb 06, 2019
Pulmatrix, Inc. Announces Termination of Planned Offering Pursuant to Registration Statement on Form S-1
Feb 05, 2019
Pulmatrix, Inc. Announces 1-for-10 Reverse Stock Split
Feb 05, 2019
Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock
Jan 31, 2019
Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock
Jan 28, 2019
Pulmatrix, Inc. Announces Pricing of Public Offering of Common Stock